JP6120778B2 - 生物学的材料の極めて特異的な捕獲および遊離のための方法および組成物 - Google Patents
生物学的材料の極めて特異的な捕獲および遊離のための方法および組成物 Download PDFInfo
- Publication number
- JP6120778B2 JP6120778B2 JP2013552696A JP2013552696A JP6120778B2 JP 6120778 B2 JP6120778 B2 JP 6120778B2 JP 2013552696 A JP2013552696 A JP 2013552696A JP 2013552696 A JP2013552696 A JP 2013552696A JP 6120778 B2 JP6120778 B2 JP 6120778B2
- Authority
- JP
- Japan
- Prior art keywords
- biological material
- molecule
- cells
- polyethylene glycol
- hydrogel composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 114
- 239000000203 mixture Substances 0.000 title claims description 107
- 239000012620 biological material Substances 0.000 title claims description 74
- 210000004027 cell Anatomy 0.000 claims description 174
- 239000000017 hydrogel Substances 0.000 claims description 128
- 229920000615 alginic acid Polymers 0.000 claims description 119
- 235000010443 alginic acid Nutrition 0.000 claims description 119
- 229920001223 polyethylene glycol Polymers 0.000 claims description 97
- 239000011230 binding agent Substances 0.000 claims description 86
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 85
- 229940072056 alginate Drugs 0.000 claims description 85
- 229920000642 polymer Polymers 0.000 claims description 81
- 239000002202 Polyethylene glycol Substances 0.000 claims description 42
- 210000000130 stem cell Anatomy 0.000 claims description 35
- 239000000783 alginic acid Substances 0.000 claims description 34
- 229960001126 alginic acid Drugs 0.000 claims description 34
- 150000004781 alginic acids Chemical class 0.000 claims description 34
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims description 32
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 29
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 27
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 27
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 20
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 20
- -1 polyethylene Polymers 0.000 claims description 20
- 239000002738 chelating agent Substances 0.000 claims description 19
- 210000004966 intestinal stem cell Anatomy 0.000 claims description 18
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 14
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 13
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 13
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 13
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 239000000816 peptidomimetic Substances 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 150000003384 small molecules Chemical class 0.000 claims description 11
- 230000003472 neutralizing effect Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 150000001768 cations Chemical class 0.000 claims description 7
- 230000003511 endothelial effect Effects 0.000 claims description 6
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 210000004504 adult stem cell Anatomy 0.000 claims description 4
- 210000003663 amniotic stem cell Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000002358 circulating endothelial cell Anatomy 0.000 claims description 4
- 210000000604 fetal stem cell Anatomy 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 210000001178 neural stem cell Anatomy 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 239000013077 target material Substances 0.000 claims description 4
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 210000002220 organoid Anatomy 0.000 description 70
- 239000000499 gel Substances 0.000 description 60
- 101150017554 LGR5 gene Proteins 0.000 description 46
- 239000000243 solution Substances 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 29
- 239000007987 MES buffer Substances 0.000 description 17
- 238000002955 isolation Methods 0.000 description 17
- 230000001640 apoptogenic effect Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000006285 cell suspension Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 206010020718 hyperplasia Diseases 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 206010011732 Cyst Diseases 0.000 description 10
- 208000031513 cyst Diseases 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000044880 Wnt3A Human genes 0.000 description 9
- 108700013515 Wnt3A Proteins 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 108010082117 matrigel Proteins 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000007640 basal medium Substances 0.000 description 6
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 101150106167 SOX9 gene Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000021164 cell adhesion Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 2
- 241000405758 Betapartitivirus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- UHLIMVWCGGKTLZ-UHFFFAOYSA-N ethane-1,2-diamine tetrahydrate Chemical compound O.O.O.O.C(CN)N UHLIMVWCGGKTLZ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000045246 noggin Human genes 0.000 description 2
- 108700007229 noggin Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000003134 paneth cell Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920005596 polymer binder Polymers 0.000 description 2
- 239000002491 polymer binding agent Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000002174 soft lithography Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IYOZTVGMEWJPKR-VOMCLLRMSA-N 4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-VOMCLLRMSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 101100058548 Felis catus BMI1 gene Proteins 0.000 description 1
- 229920002430 Fibre-reinforced plastic Polymers 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102100034026 RNA-binding protein Musashi homolog 1 Human genes 0.000 description 1
- 101710129077 RNA-binding protein Musashi homolog 1 Proteins 0.000 description 1
- 229920001486 SU-8 photoresist Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical group ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000011151 fibre-reinforced plastic Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000010069 protein adhesion Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
- B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
- B01F25/43—Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
- B01F25/431—Straight mixing tubes with baffles or obstructions that do not cause substantial pressure drop; Baffles therefor
- B01F25/4317—Profiled elements, e.g. profiled blades, bars, pillars, columns or chevrons
- B01F25/43172—Profiles, pillars, chevrons, i.e. long elements having a polygonal cross-section
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
- B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
- B01F25/43—Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
- B01F25/431—Straight mixing tubes with baffles or obstructions that do not cause substantial pressure drop; Baffles therefor
- B01F25/43197—Straight mixing tubes with baffles or obstructions that do not cause substantial pressure drop; Baffles therefor characterised by the mounting of the baffles or obstructions
- B01F25/431971—Mounted on the wall
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0636—Focussing flows, e.g. to laminate flows
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0652—Sorting or classification of particles or molecules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/069—Absorbents; Gels to retain a fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0478—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161439166P | 2011-02-03 | 2011-02-03 | |
| US61/439,166 | 2011-02-03 | ||
| PCT/US2012/023859 WO2012106658A1 (en) | 2011-02-03 | 2012-02-03 | Methods and compositions for highly specific capture and release of biological materials |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016238320A Division JP2017077245A (ja) | 2011-02-03 | 2016-12-08 | 生物学的材料の極めて特異的な捕獲および遊離のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506671A JP2014506671A (ja) | 2014-03-17 |
| JP2014506671A5 JP2014506671A5 (enExample) | 2015-03-26 |
| JP6120778B2 true JP6120778B2 (ja) | 2017-04-26 |
Family
ID=46603107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552696A Active JP6120778B2 (ja) | 2011-02-03 | 2012-02-03 | 生物学的材料の極めて特異的な捕獲および遊離のための方法および組成物 |
| JP2016238320A Abandoned JP2017077245A (ja) | 2011-02-03 | 2016-12-08 | 生物学的材料の極めて特異的な捕獲および遊離のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016238320A Abandoned JP2017077245A (ja) | 2011-02-03 | 2016-12-08 | 生物学的材料の極めて特異的な捕獲および遊離のための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9927334B2 (enExample) |
| EP (1) | EP2670856B1 (enExample) |
| JP (2) | JP6120778B2 (enExample) |
| KR (1) | KR101922741B1 (enExample) |
| ES (1) | ES2687144T3 (enExample) |
| SG (2) | SG10201600803SA (enExample) |
| WO (1) | WO2012106658A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014072465A1 (en) | 2012-11-09 | 2014-05-15 | Roche Diagnostics Gmbh | In vitro capture and analysis of circulating tumor cells |
| WO2014121204A1 (en) * | 2013-02-01 | 2014-08-07 | The General Hospital Corporation | Capture and release of particles from liquid samples |
| US20170074870A1 (en) | 2014-03-14 | 2017-03-16 | Northeastern University | Microfluidic System and Method for Real-Time Measurement of Antibody-Antigen Binding and Analyte Detection |
| WO2015148512A1 (en) | 2014-03-24 | 2015-10-01 | Qt Holdings Corp | Shaped articles including hydrogels and methods of manufacture and use thereof |
| PT3237597T (pt) * | 2014-12-22 | 2021-03-12 | Ecole Polytechnique Fed Lausanne Epfl | Dispositivos para agregação de alto rendimento e manipulação de células de mamífero |
| US9790467B2 (en) * | 2015-09-22 | 2017-10-17 | Qt Holdings Corp | Methods and compositions for activation or expansion of T lymphocytes |
| ES2871137T3 (es) * | 2015-12-14 | 2021-10-28 | Quanta Matrix Co Ltd | Método de diferenciación de células particulares a partir de la mezcla de células heterogéneas |
| SG11201808014SA (en) | 2016-03-18 | 2018-10-30 | Qt Holdings Corp | Compositions, devices, and methods for cell separation |
| US10429387B2 (en) * | 2016-07-27 | 2019-10-01 | Universiteit Tweate | Simple and affordable method for immuophenotyping using a microfluidic chip sample preparation with image cytometry |
| US11118163B2 (en) | 2017-02-02 | 2021-09-14 | Sartorius Stedim Biotech Gmbh | Separation of cell populations by marker identification and sedimentation velocity |
| DE102017105195A1 (de) | 2017-03-10 | 2018-09-13 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Verfahren zur differenzierten Sequestrierung von Stoffen verschiedener Stoffgruppen mit Hilfe von sulfatierte oder sulfonierte Komponenten enthaltenden Hydrogelen |
| US20200085971A1 (en) * | 2017-03-20 | 2020-03-19 | Qt Holdings Corp | Methods and compositions for modulation of immune cells |
| WO2019239359A2 (en) | 2018-06-13 | 2019-12-19 | University Of Washington | Extruded hydrogel tubes and coaxial fibers and applications thereof |
| DK3626814T3 (da) * | 2018-09-21 | 2023-06-06 | Univ Wien Tech | Fremstilling af cellesfæroider |
| JP7120547B2 (ja) * | 2019-02-22 | 2022-08-17 | 国立研究開発法人理化学研究所 | 物質固定化剤、及び当該物質固定化剤を用いた物質固定化方法 |
| EP3941630B1 (en) * | 2019-03-18 | 2025-04-16 | Cellular Research, Inc. | Precise delivery of components into fluids |
| US11668676B2 (en) * | 2019-05-30 | 2023-06-06 | The Regents Of The University Of California | Microfluidic acoustic devices and methods |
| CN112708150B (zh) * | 2020-12-08 | 2021-11-16 | 济南国科医工科技发展有限公司 | 用于循环肿瘤细胞的捕获及定点释放的水凝胶体系 |
| KR20240051155A (ko) | 2021-09-01 | 2024-04-19 | 바이오-테크네 코포레이션 | 인간 비트로넥틴 단편 및 이의 용도 |
| US11805995B1 (en) | 2022-11-22 | 2023-11-07 | King Faisal University | Saliva collection kit |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU733716B2 (en) * | 1996-09-19 | 2001-05-24 | Regents Of The University Of Michigan, The | Polymers containing polysaccharides such as alginates or modified alginates |
| US20050065281A1 (en) | 2001-11-07 | 2005-03-24 | Mathias Lutolf | Synthetic matrix for controlled cell ingrowth and tissue regeneration |
| ES2301697T3 (es) * | 2001-12-18 | 2008-07-01 | Eidgenossisch Technische Hochschule Zurich | Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos. |
| WO2004008142A1 (ja) * | 2002-07-12 | 2004-01-22 | Mitsubishi Chemical Corporation | 分析用チップ、分析用チップユニット、分析装置及びそれを用いた分析方法並びに分析用チップの作製方法 |
| EP1569510B1 (en) * | 2002-09-27 | 2011-11-02 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
| TW200605910A (en) | 2004-04-30 | 2006-02-16 | Orbus Medical Technologies Inc | Medical device with coating for capturing genetically-altered cells and methods for using same |
| SE0402476D0 (sv) * | 2004-10-13 | 2004-10-13 | Biacore Ab | Preparation and use of a reactive solid support surface |
| CN101338036B (zh) * | 2007-07-06 | 2010-11-03 | 常州百瑞吉生物医药有限公司 | 生物相容快速凝胶化水凝胶及其喷雾剂的制备方法 |
| US9267109B2 (en) * | 2007-12-10 | 2016-02-23 | Koninklijke Philips N.V. | Patterned cell sheets and a method for production of the same |
| US20120077246A1 (en) | 2009-04-24 | 2012-03-29 | The Board Of Trustees Of The University Of Illinoi | Methods and Devices for Capturing Circulating Tumor Cells |
| US20140154703A1 (en) * | 2011-01-06 | 2014-06-05 | Alison Skelley | Circulating tumor cell capture on a microfluidic chip incorporating both affinity and size |
-
2012
- 2012-02-03 SG SG10201600803SA patent/SG10201600803SA/en unknown
- 2012-02-03 EP EP12742728.4A patent/EP2670856B1/en active Active
- 2012-02-03 WO PCT/US2012/023859 patent/WO2012106658A1/en not_active Ceased
- 2012-02-03 US US13/982,680 patent/US9927334B2/en active Active
- 2012-02-03 SG SG2013058797A patent/SG192587A1/en unknown
- 2012-02-03 ES ES12742728.4T patent/ES2687144T3/es active Active
- 2012-02-03 KR KR1020137023006A patent/KR101922741B1/ko active Active
- 2012-02-03 JP JP2013552696A patent/JP6120778B2/ja active Active
-
2016
- 2016-12-08 JP JP2016238320A patent/JP2017077245A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2670856A1 (en) | 2013-12-11 |
| JP2014506671A (ja) | 2014-03-17 |
| JP2017077245A (ja) | 2017-04-27 |
| SG192587A1 (en) | 2013-09-30 |
| EP2670856A4 (en) | 2014-12-03 |
| EP2670856B1 (en) | 2018-06-27 |
| US9927334B2 (en) | 2018-03-27 |
| WO2012106658A1 (en) | 2012-08-09 |
| SG10201600803SA (en) | 2016-03-30 |
| ES2687144T3 (es) | 2018-10-23 |
| KR20140016896A (ko) | 2014-02-10 |
| US20140057280A1 (en) | 2014-02-27 |
| KR101922741B1 (ko) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6120778B2 (ja) | 生物学的材料の極めて特異的な捕獲および遊離のための方法および組成物 | |
| AU2018390960B2 (en) | Immune cell organoid co-cultures | |
| Truong et al. | A three-dimensional (3D) organotypic microfluidic model for glioma stem cells–Vascular interactions | |
| Cherne et al. | A synthetic hydrogel, VitroGel® ORGANOID-3, improves immune cell-epithelial interactions in a tissue chip co-culture model of human gastric organoids and dendritic cells | |
| Kwizera et al. | Greatly enhanced CTC culture enabled by capturing CTC heterogeneity using a PEGylated PDMS–Titanium–Gold electromicrofluidic device with glutathione-controlled gentle cell release | |
| ES2542070T3 (es) | Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas para la reparación y regeneración de tejido blando | |
| BR112016024072B1 (pt) | método in vitro de estimular uma população de células | |
| TW200411059A (en) | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use | |
| KR102029156B1 (ko) | 순환종양세포 검출용 미세유체칩 | |
| JP2017512314A (ja) | 末梢循環腫瘍細胞を捕獲するための生体模倣マイクロ流体装置 | |
| Kratzer et al. | Nanostructured bifunctional hydrogels as potential instructing platform for hematopoietic stem cell differentiation | |
| Liu et al. | Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies | |
| JP7501875B2 (ja) | 血液凝固および／または補体異常疾患の治療用組成物 | |
| Maulana et al. | Solid tumor-on-chip model for efficacy and safety assessment of CAR-T cell therapy | |
| Lansche et al. | Bioengineering a Patient‐Derived Vascularized Lung Tumor‐on‐Chip Model to Decipher Immunomodulation by the Endothelium | |
| KR101616705B1 (ko) | 특이적 결합분자―나노섬유 복합체 및 이를 이용한 세포활성화 방법 | |
| Li et al. | Synthetic viscoelastic activating cells for T cell engineering and cancer therapy | |
| Hirth | Development of a microfluidic platform to emulate the human microvasculature | |
| Kevlahan | A microfluidic capture and release method for isolation intestinal progenitor and stem cells from native rat tissue enabling advances in vasculogenic co-cultures | |
| Liu et al. | Manufacturing synthetic viscoelastic antigen-presenting cells for immunotherapy | |
| Hatch | Microfluidic isolation of endothelial progenitor cells for vascular tissue engineering | |
| WO2024052906A1 (en) | Activation and proliferation of cytotoxic lymphocytes | |
| Sun et al. | Prediction of CAR‐T Therapy In Vitro: Development of Biomimetic Models for CAR‐T Killing Effect Assessment | |
| WO2025117475A1 (en) | Treatment of multiorgan failure with autologous pluripotent stem cell derived therapies | |
| Silangcruz | Micropatterned Aptamer-Containing Surfaces for Capturing CD4 T-cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160127 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160627 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161208 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170227 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170328 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6120778 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |